This open-label, multicenter, dose-escalation study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO5509554 in patients with advanced solid tumors which are not amenable to standard treatment. In Part I, multiple ascending doses of RO5509554 will be administered as monotherapy in patients with solid tumors. Patients with locally advanced and/or metastatic ovarian and breast carcinoma will receive multiple ascending doses of RO5509554 in combination with paclitaxel. In Part II, RO5509554 will be administered as monotherapy to patients with pigmented tenosynovial giant cell tumor (PVNS), tenosynovial giant cell tumor (TGCT), ovarian cancer or breast cancer. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

Open-label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors.

Pharmacokinetics: Plasma concentrations of RO5509554 [ Time Frame: Pre-dose, end of infusion and 2, 3, 4, 5, 6, 24, 72 or 96, and 168 hours post-dose Cycles 1-4, pre-dose and end of infusion on Day 1 every following cycle ] [ Designated as safety issue: No ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01494688